» Articles » PMID: 34567208

Evaluation of Rabbits Liver Fibrosis Using Gd-DTPA-BMA of Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Overview
Date 2021 Sep 27
PMID 34567208
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the different pharmacokinetic parameters of the DCE-MRI method on diagnosing and staging of rabbits' liver fibrosis.

Methods: We had performed DCE-MRI for rabbits that had been divided into the experiment group and the control group. Then, rabbits' images were transferred to a work station to get three parameters such as , , and , which had been measured to calculate. After data were analyzed, ROC analyses were performed to assess the diagnostic performance of , , and to judge liver fibrosis.

Results: The distribution of the different liver fibrosis group was as follows: F1,  = 8; F2,  = 9; F3,  = 6; F4,  = 5. No fibrosis was deemed as F0,  = 6. is statistically significant ( < 0.05) for F0 and mild liver fibrosis stage, and the shows AUC of 0.814. Three parameters are statistically significant for F0 and advanced liver fibrosis stage ( and , < 0.01; , < 0.05), and the shows AUC of 0.924; the shows AUC of 0.909; the shows AUC of 0.848; and are statistically significant for mild and advanced liver fibrosis stages ( , < 0.01; , < 0.05), and the shows AUC of 0.840; the shows AUC of 0.765. Both and are negatively correlated with the liver fibrosis stage. is positively correlated with the liver fibrosis stage.

Conclusion: is shown to be the best DCE parameter to distinguish the fibrotic liver from the normal liver and mild and advanced fibrosis. On the contrary, is moderate and is worst. And is a good DCE parameter to differentiate mild fibrosis from the normal liver.

Citing Articles

Retracted: Evaluation of Rabbits Liver Fibrosis Using Gd-DTPA-BMA of Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

And Alternative Medicine E Evid Based Complement Alternat Med. 2023; 2023:9816867.

PMID: 37388113 PMC: 10307165. DOI: 10.1155/2023/9816867.

References
1.
Bravo A, Sheth S, Chopra S . Liver biopsy. N Engl J Med. 2001; 344(7):495-500. DOI: 10.1056/NEJM200102153440706. View

2.
Goncalves R, Novaes R, Sarandy M, Leite J, Vilela E, Cupertino M . Schizocalyx cuspidatus (A. St.-Hil.) Kainul. & B. Bremer extract improves antioxidant defenses and accelerates the regression of hepatic fibrosis after exposure to carbon tetrachloride in rats. Nat Prod Res. 2016; 30(23):2738-2742. DOI: 10.1080/14786419.2016.1143825. View

3.
Rosenberg W, Voelker M, Thiel R, Becka M, Burt A, Schuppan D . Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004; 127(6):1704-13. DOI: 10.1053/j.gastro.2004.08.052. View

4.
Stasi C, Milani S . Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol. 2016; 22(4):1711-20. PMC: 4722001. DOI: 10.3748/wjg.v22.i4.1711. View

5.
Venkatesh S, Yin M, Takahashi N, Glockner J, Talwalkar J, Ehman R . Non-invasive detection of liver fibrosis: MR imaging features vs. MR elastography. Abdom Imaging. 2015; 40(4):766-75. PMC: 4739358. DOI: 10.1007/s00261-015-0347-6. View